A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema,Oliguria,and Acute Kidney Injury: A Case Report

Abstract

Get full access to this article

View all access options for this article.

References

Fact Sheet for Healthcare Providers. Emergency use authorization for Paxlovid™. Published December 2021. Accessed October 24, 2022. https://labeling.pfizer.com/ShowLabeling.aspx?id=16474

Marzolini

Kuritzkes

Marra

, et al. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications. Clin Pharmacol Ther. 2022;112(6):1191-1200. doi:10.1002/cpt.2646

Niu

Jin

, et al. Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: a physiologically based pharmacokinetic/pharmacodynamic analysis. Br J Clin Pharmacol. 2021;87(7):2790-2806. doi:10.1111/bcp.14684

Stader

Khoo

Stoeckle

, et al. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. J Antimicrob Chemother. 2020;75(10):3084-3086. doi:10.1093/jac/dkaa253

Baeza

Merino

Boix

Climent

. Nifedipine-lopinavir/ritonavir severe interaction: a case report. AIDS. 2007;21(1):119-120. doi:10.1097/QAD.0b013e3280117f6f

Rossi

Rathbun

Slater

. Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacotherapy. 2002;22(10):1312-1316. doi:10.1592/phco.22.15.1312.33478

Shah

Self

Bradsher

III Owens

. Clarithromycin-nifedipine-induced acute kidney injury. Nurse Pract. 2017;42(9):49-51. doi:10.1097/01.NPR.0000521991.15440.a7

Horn

Hansten

Chan

. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674-680. doi:10.1345/aph.1H423

Italia

Tomasoni

Bisegna

, et al. COVID-19 and heart failure: from epidemiology during the pandemic to myocardial injury, myocarditis, and heart failure sequelae. Front Cardiovasc Med. 2021;8:713560. doi:10.3389/fcvm.2021.713560

10.

Pranata

Huang

Lukito

Raharjo

. Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Postgrad Med J. 2020;96(1137):387-391. doi:10.1136/postgradmedj-2020-137884